Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Frankfurt – page 73

968 clinical trials in Frankfurt, Germany across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Frankfurt at a glance
968
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

968 trials in Frankfurt

Open in trial search

Breast cancer+3

Not recruiting

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Colorectal cancer metastatic

Not recruiting

Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:NSABP Foundation Inc.

Cholangiocarcinoma+1

Not recruiting

Study on the Effectiveness and Safety of Gemcitabine, Cisplatin, Trastuzumab, and Pembrolizumab for Untreated HER2-Positive Biliary Tract Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Colorectal cancer metastatic

Not recruiting

Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Non-small cell lung cancer

Not recruiting

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of SAR441566 for Adults with Moderate to Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sar441566
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Factor VIII deficiency

Not recruiting

Study on the Safety and Effects of BAY 2599023 (Peboctocogene Camaparvovec) for Adults with Severe Hemophilia A

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Peboctocogene Camaparvovec
  • Sponsor:Bayer AG

Cystic fibrosis

Not recruiting

Study on the Effects of Inhaled ETD001 for People with Cystic Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:3-Amino-N-{[5-[4-[Bis[(2S,3R,4R,5R)-2,3,4,5,6-Pentahydroxyhexyl]Amino]Piperidine-1-Carbonyl]-1,3-Diethyl-Benzimidazol-1-Ium-2-Yl]Methyl}-5H-Pyrrolo[2,3-B]Pyrazine-2-Carboxamide Dihydrochloride Chloride
  • Sponsor:Enterprise Therapeutics Limited

Study of Tislelizumab, Dacarbazine, Vinblastine Sulfate, and Doxorubicin Hydrochloride for Adults with Early-Stage Unfavorable Hodgkin Lymphoma

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:University Of Cologne

Chronic spontaneous urticaria

Not recruiting

Study on the Effects of Briquilimab in Adults with Chronic Spontaneous Urticaria Unresponsive to Antihistamines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Briquilimab
  • Sponsor:Jasper Therapeutics Inc.

Adenocarcinoma pancreas

Not recruiting

Study on the Effectiveness and Safety of Autogene Cevumeran, Atezolizumab, and mFOLFIRINOX in Patients with Resected Pancreatic Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Genentech Inc.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Frankfurt

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on hematologic malignancies and solid tumors, including innovative treatments for lymphoma, leukemia, and various gastrointestinal cancers.

  • Chronic Lymphocytic Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Gastric Cancer
  • Pancreatic Cancer

Studies evaluate novel therapeutic combinations and targeted treatments to improve patient outcomes.

02 Gastrointestinal Disorders

Research initiatives examining treatments for inflammatory bowel conditions, including Crohn's Disease and Ulcerative Colitis, with emphasis on long-term management approaches.

  • Moderate to Severe UC
  • Active Crohn's Disease
  • GI Tract Infections

Focus on innovative therapeutic options for chronic inflammatory conditions.

03 Rare Diseases

Clinical investigations of treatments for rare conditions, including Von Willebrand Disease and Dravet Syndrome, exploring novel therapeutic approaches.

  • Blood Disorders
  • Genetic Conditions
  • Neurological Disorders

Development of targeted therapies for previously difficult-to-treat conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.